Splash Beverage enters development collaboration with Lupvindol for veterinary drug from CannEpil

SPLASH BEVERAGE GROUP, INC.

Lupvindol to lead FDA INAD and conditional approval for CannEpil-based veterinary product in companion-animal oncology and pain.
Milestone payments total up to $1.11M plus 4% royalty on net sales (or equity election) upon conditional approval or earlier licensing.
Splash provides milestone funding and commercial support; Lupvindol handles development and regulatory activities.
Initial term 5 years, auto-renew; Splash can terminate for convenience with 90 days notice and wind-down fee equal to next milestone.
Collaboration follows July 2026 exclusive license from Argent Biopharma (RGT) for CannEpil; royalty to RGT is 10% of net revenue for veterinary use.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.